Research Article

ERK1/2-Dependent Inhibition of Glycolysis in Curcumin-Induced Cytotoxicity of Prostate Carcinoma Cells

Yoon-Jin Lee and Sang-Han Lee

Department of Biochemistry, College of Medicine, Soonchunhyang University, Cheonan 31151, Republic of Korea

Correspondence should be addressed to Yoon-Jin Lee; leeyj@sch.ac.kr

Received 15 February 2022; Revised 8 August 2022; Accepted 10 August 2022; Published 24 August 2022

Academic Editor: Ferdinando Chiaradonna

Copyright © 2022 Yoon-Jin Lee and Sang-Han Lee. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Object. Extracellular acidosis of the tumor microenvironment plays an important role in cancer progression. In the 2D monolayer and 3D spheroid cultures of prostate cancer cells, we investigated the efficacy of curcumin in targeting glycolysis and the role of ERK1/2 as an upstream signaling molecule in this process.

Methods. Cell viability, glycolytic activity, Annexin V-PE binding activity, reactive oxygen species levels, mitochondrial membrane potential, ATP content, Western blot analysis, and spheroid viability were measured for this study.

Results. Acidic pH-tolerant prostate cancer cells, PC-3AcT and DU145AcT, increased cytotoxicity with ERK1/2 inhibition in a curcumin concentration-dependent manner at concentrations that resulted in >90% cell viability in normal prostate epithelial HPrEC cells. ERK1/2 inhibition by curcumin and/or PD98059 suppressed cell growth, reduced glucose consumption, and downregulated the expression of key regulatory enzymes in glucose metabolism including hexokinases, phosphofructokinase, and pyruvate dehydrogenase. In addition, these compounds caused loss of mitochondrial membrane potential with increased intracellular ROS levels, decreased levels of complexes I, III, and IV in the mitochondrial electron transport chain, and cellular ATP depletion, leading to upregulation of marker proteins in apoptosis (cleaved caspase-3 and cleaved PARP) and necroptosis (p-MLKL and p-RIP3). The results of curcumin and/or PD98059 treatment in 3D cultures showed similar trends to those in 2D cultures.

Conclusion. Taken together, the results provide mechanistic evidence for the antiglycolytic and cytotoxic roles of curcumin through inhibition of the MEK/ERK signaling pathway in prostate carcinoma cells preadapted to acidic conditions.

1. Introduction

Glycolysis is a metabolic pathway that consists of a series of consecutive enzymatic reactions for glucose oxidation by which most living organisms break down glucose into pyruvate, providing both energy and intermediates for further use. Pyruvate is further metabolized in the mitochondria by tricarboxylic acid cycle and oxidative phosphorylation through the electron transport chain (ETC) to produce the cell’s energy currency, adenosine triphosphate (ATP). Under anaerobic conditions, cells oxidize NADH to NAD⁺, reducing pyruvate to lactate, which produces a much smaller amount of ATP but occurs at a much faster rate [1].

Regardless of oxygen availability, the higher dependence of cancer cells on glycolysis rather than oxidative phosphorylation for ATP production, known as the Warburg effect [2], is recognized as one of the most fundamental changes in cancer progression. This metabolic reprogramming is less energy efficient, but due to the acceleration of the process, it not only produces faster and greater energy than oxidative phosphorylation but also provides metabolic intermediates or precursors for enhanced tumor growth [3]. Excessive glycolysis produces large amounts of lactate and allows excessive intracellular acid loads to be released into the extracellular compartment, causing the extracellular pH to acidify. Adapting cancer cells to the acidic tumor microenvironment plays an important role in increasing chemoresistance and enhancing invasion and metastasis, suggesting the importance of the Warburg effect in tumor progression [4]. Therefore, taking into account the importance of
extracellular acidic pH, a strategy to target cells adapted to this environment will facilitate the discovery of more effective therapeutics.

Several regulatory molecules, including phosphatidylinositol 3 (PI3) kinases/protein kinase B (Akt), c-Myc, and hypoxia inducible factor-1 (HIF-1), influence the metabolic shift of energy production to the Warburg phenotype during carcinogenesis and support anabolic requirements [5]. Enhanced mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling can also promote the Warburg effect through the ERK1/2 phosphorylation-dependent nuclear translocation of pyruvate kinase muscle isoform 2 (PKM2), thereby increasing the expression of genes involved in the glycolysis [6]. The important role of the RAF/MEK/ERK pathway in promoting the Warburg-like effects in cancer has been further studied in vitro and in vivo mouse models [7, 8]. Therefore, targeting aerobic glycolysis or its upstream modulators has become a promising therapeutic strategy for inhibiting cancer progression. Several inhibitors of glycolysis, such as the hexokinase II (HK-II) inhibitors ionidamine and 2-deoxy-D-glucose, the pyruvate dehydrogenase kinase inhibitor dichloroacetate, or the PI3-kinase/Akt inhibitor auresertib, have been evaluated in preclinical and clinical trials for therapeutic efficacy [9].

Curcumin, a linear diarylheptanoid belonging to curcuminoid family, is a bright yellow polyphenolic compound found in the rhizome of Curcuma longa L. The responses to curcumin are cell type-specific due to its different modes of action and different targets [10]. Numerous studies have shown that the growth inhibitory effect of curcumin on various tumor cells is mediated through actions on numerous molecules in the signaling pathway, including p53, NF-κB, mitogen-activated protein kinases (MAPK), Akt/mammalian target of rapamycin (mTOR), Notch-1, nuclear factor erythroid 2-related factor 2 (Nrf2), Wnt/β-catenin, Janus kinase (JAK)/signal transducer and activator of transcription (STAT), and AMP-activated protein kinase (AMPK) [11]. Recently, curcumin has been reported to suppress the Warburg effect in various cancer cell lines by downregulating PKM2 expression through inhibition of the mTOR/HIF-1α axis [12]. However, there are few reports of the effect of curcumin on energy metabolism in prostate cancer.

In a previous study, we reported the preferential cytotoxicity and mechanism of curcumin on PC-3AcT cells that showed high resistance to docetaxel, compared to parental PC-3 cells [13]. Interestingly, curcumin was shown to have the activity of coinducing apoptosis and necroptosis by increasing reactive oxygen species (ROS) production and decreasing intracellular ATP content in human prostate carcinoma cells preadapted to lactic acid-containing media. The study presented in this paper is aimed at further evaluating the effect of curcumin on aerobic glycolysis and the relevance of ERK1/2 activity as an upstream signaling molecule in prostate carcinoma cells.

2. Methods

2.1. Cell Cultures and Assays. Acidic pH-tolerant cells designated as PC-3AcT and DU145AcT cells were established by continuously exposing human prostate cancer cell lines PC-3 and DU145 cells (ATCC), respectively, to 3.8 μM lactic acid through 4 serial passage for 15 days. PC-3AcT and DU145AcT cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) containing 3.8 μM lactic acid and 5% fetal bovine serum. The human prostate epithelial cell line HPrEC (ATCC) was maintained in prostate epithelial cell basal medium supplemented with the Prostate Epithelial Cell Growth Kit (ATCC). Cells (5 × 10⁵ cells/well) were seeded in 96-well plates 24 h prior to treatment with 0.1% dimethylsulfoxide (Sigma-Aldrich) as a negative control, or different concentrations of curcumin (Sigma-Aldrich) and/or PD98059 (Sigma-Aldrich). Cell viability was measured by MTT assay as previously described [13]. HK activity was measured spectrophotometrically according to the instructions provided with the Hexokinase Colorimetric Assay Kit (BioVision Inc.). Pyruvate dehydrogenase (PDH) activity was quantified with the Pyruvate Dehydrogenase Activity Colorimetric Assay Kit according to the manufacturer’s instructions (BioVision Inc.). Glucose consumption was determined by measuring the glucose content in the culture media according to the instruction provided in the Glucose Colorimetric Assay Kit (BioVision Inc.). Intracellular ATP content was determined by luminescence measurement using the CellTiter-Glo Luminescent Cell Viability Assay Kit according to the manufacturer’s instructions (Promega Corporation). The data were normalized by the number of viable cells. Absorbance and luminescence values were measured by a GloMax-Multi microplate multimode reader (Promega Corporation).

2.2. Western Blot Analysis. Total cell lysates were extracted with l× RIPA buffer and protein concentration was determined by BCA protein assay (Thermo Scientific). The extracted proteins (40 μg/well) were separated on 4-12% NuPAGE gels (Thermo Fisher Scientific) and then transferred to polyvinylidene fluoride membrane (GE Healthcare Life Science). The membranes were blocked with 1× casein solution (Thermo Fisher Scientific) for 2 h, incubated overnight at 4°C with primary antibodies, and then with horseradish-peroxidase- (HRP-) conjugated secondary antibodies for 2 h at room temperature. Reactive proteins were visualized by enhanced chemiluminescence detection kit (Cyanagen) with X-ray film. Oxphos human WB antibody cocktail (#45-8199) and antibodies to HK-1 (#2024; 1:500 dilution), HK-II (#2867; 1:500 dilution), PFKP (#8164; 1:500 dilution), PDH (#3205; 1:500 dilution), p-MLKL (#91689; 1:500 dilution), p-RIP3 (#93654; 1:500 dilution), ERK1/2 (#9102; 1:500 dilution), p-ERK1/2 (#9101; 1:500 dilution), PARP (#9542; 1:500 dilution), cleaved PARP (#9541; 1:500 dilution), caspase-3 (#9665; 1:500 dilution), and cleaved caspase-3 (#9664; 1:500 dilution) were purchased from Cell Signaling Technology and used for antigen detection. Antibodies to MEK1/2 (sc-436; 1:500 dilution) and p-MEK1/2 (sc-7995; 1:500 dilution), goat anti-rabbit IgG-HRP (sc-2004; 1:5,000 dilution), and goat anti-mouse IgG-HRP (sc-2005; 1:5,000 dilution) were purchased from Santa-Cruz Biotechnology. The membrane was reprobed with anti-β-actin (Sigma-Aldrich, A2228; 1:10,000 dilution), anti-RIP3 (Cell Signaling Technology,
Figure 1: Continued.
2.3. Cell Cycle Analysis. The cell cycle distribution at each phase was determined by propidium iodide (PI) staining. Briefly, trypanized cells were centrifuged at 500 × g at 4°C for 7 min and then fixed at -20°C overnight using 70% ethanol. After washing with 1× phosphate-buffered saline, the cells were incubated with the Muse cell cycle reagent (Merck KGaA). Data from 10,000 cells were analyzed using the MACSQuant analyzer and MACSQuantify software version 2.5 (Miltenyi Biotec GmbH).

2.4. Annexin V-PE Binding Assay. The analysis of apoptosis and necrotic cell distribution was performed according to the instructions provided with the Muse Annexin V & Dead Cell Assay Kit (Merck KGaA). Briefly, the cells were treated with curcumin (40 μM) and/or PD98059 (50 μM) in the lactic acid-containing DMEM at 37°C for 48 h, then trypsinized and collected into a culture medium supplemented with the Muse Annexin V & Dead Cell reagent, and analyzed by Muse cell analyzer (Merck KGaA). Annexin V-phycoerythrin- (PE-) positive apoptotic and 7-amino-actinomycin D- (7-AAD-) positive necrotic cells were detected using Annexin V-PE and 7-AAD double staining.

2.5. DAPI Staining. Nuclear fragmentation and chromatin condensation were observed by 4′,6-diamidino-2-phenylindole (DAPI) staining according to the methods of Lee and Lee [14]. Cells (10⁵ cells/well) were seeded into a 6-well culture plate and incubated with curcumin (40 μM) and/or...
PD98059 (50 μM) in the lactic acid-containing DMEM at 37°C for 48 h. The cells were spread out on the slide and the coverslip was mounted using a mounting medium (Poly-science, Inc.). Apoptotic cells were visualized using a Leica EL6000 fluorescence microscope (Olympus Corporation).

2.6. Measurement of ROS and Mitochondrial Membrane Potential. Cells were seeded on 6-well culture plates at 10⁵ cells/well, 24 h prior to treatment with PD98059 (50 μM) or curcumin (40 μM) in lactic acid-containing DMEM for 48 h. Following trypsinization, cells were harvested by centrifugation at 500x g for 7 min and then resuspended in serum-free DMEM containing 10 μM 2',7'-dichlorodihydrofluorescein diacetate (DCF-DA) (Sigma-Aldrich) and 30 nM Rhodamine 123 (Sigma-Aldrich) in the dark at 37°C for 30 min to measure the levels of ROS and mitochondrial potential.

![Figure 2: Antiglycolytic effects of curcumin in 3D spheroid culture. Spheroids were cultured in ultralow cluster plates and were treated with the indicated concentrations of curcumin in DMEM containing 3.8 μM lactic acid for 48 h. (a) Vitality staining of spheroids: (i) phase-contrast image, (ii) fluorescent image of fluorescein diacetate(+) live cells in green, (iii) propidium iodide(+) dead cells in red, and (iv) merged. (b) Spheroid viability. (c) The expression levels of p-MEK, p-ERK1/2, and rate-limiting enzymes in glucose metabolism. (d) The expression levels of complexes I-V in the mitochondrial electron transport chain. *P < 0.05 vs. respective control cells. CCM: curcumin; PD: PD98059; HK: hexokinase; PFKP: phosphofructokinase platelet; PDH: pyruvate dehydrogenase.](image-url)
membrane potential, respectively. The fluorescence intensity of the cells was measured with a MACSQuant analyzer and MACSQuantify software version 2.5 (MiltenyiBiotec GmbH).

2.7. Spheroid Culture and Viability Assay. Spheroid culture was performed in an ultralow attachment 96-well plates as previously described [13]. Briefly, plates seeded with $10^4$ cells/well were centrifuged at 1,000 rpm for 10 min to allow
Figure 4: Continued.
cells to cluster in the wells and maintained in complete DMEM containing lactic acid (final concentration: 3.8 μM) for 5 days. Spheroids were treated with curcumin (40 μM) and/or PD98059 (50 μM) for 48 h. A two-color fluorescence assay was used to identify live and dead cells. Cell-permeable fluorescein diacetate (FDA, Sigma-Aldrich, 5 μg/mL) is converted into green fluorescence by esterases within living cells, whereas PI (Sigma-Aldrich, 10 μg/mL) enters the nucleus of dead or dying cells and emits red fluorescence upon binding to DNA. Phase-contrast images were acquired with a Leica inverted microscope. Spheroids were visualized using a Leica EL6000 fluorescence microscope (Leica Microsystems GmbH). Spheroid viability was determined according to the instructions provided with the Enhanced Cell Viability Assay Kit (Young In Frontier). Briefly, 10 μL of Cellvia solution was added to each well, kept at room temperature for 1 h, and then mixed by shaking for 1 min. The amount of formazan formed in living cells was measured spectrophotometrically at 450 nm using a GloMax-Multi microplate multimode reader (Promega Corporation).

2.8. Statistical Analysis. SPSS version 17.0 software (SPSS, Inc.) was used for statistical analysis of experimental data. Statistical analysis was performed by one-way ANOVA and Tukey’s post hoc correction. Data are presented as mean ± standard deviation (S.D.) for three independent experiments. P < 0.05 was considered statistically significant.

3. Results

3.1. Effects of Curcumin on MEK/ERK1/2 Phosphorylation, Glycolysis, and Electron Transport Chain. To find the upstream signaling molecule regulated by curcumin, the effect of curcumin treatment on the MEK/ERK signaling pathway was examined in culture medium containing 3.8 μM lactic acid. Herein, preferential chemotoxicity to prostate cancer cells while sparing normal cells was an important consideration for potential therapeutic candidates. As shown in Figure 1(a), at a concentration exhibiting a cell viability of 90% or more in normal prostate epithelial HPrEC cells, curcumin significantly increased the cytotoxicity of PC-3AcT and DU145AcT cells, although the inhibition of cell growth was stronger in PC-3AcT cells (IC50 = 42.8 μM) than DU145AcT cells (IC50 = 54.9 μM). Phosphorylation of MEK1/2 and ERK1/2 was inhibited in cultures treated with ≥20 μM curcumin and more pronounced at 40 μM compared to HPrEC cells (Figure 1(b)). In addition, the levels of several rate-limiting enzymes in glucose metabolism, including HK-I, HK-II, phosphofructokinase platelet (PFKP), and pyruvate dehydrogenase (PDH), were decreased in PC-3AcT and DU145AcT cells in a curcumin concentration-dependent manner (Figure 1(c)). Consistently, the activities of HK and PDH decreased in the same pattern as the result of Western blotting (Figure 1(d)). We then analyzed the levels of the five complexes in the mitochondrial electron transport chain (ETC). An obvious decrease was observed in complexes I NADH-ubiquinone oxidoreductase subunit B8 (NDUFB8), III ubiquinone-cytochrome C reductase core protein 2 (UQCRC2), and IV mitochondrial cytochrome C oxidase subunit II (COX II) in curcumin-treated PC-3AcT and DU145AcT cells when compared to HPrEC cells (Figure 1(e)).

Based on the results in 2D monolayer cultures, we further investigated the effect of curcumin on the growth of spheroids and the expression levels of the p-ERK1/2 as well as glycolytic and ETC proteins in 3D spheroid culture. As shown in Figure 2(a), curcumin decreased spheroid growth with an increase in red fluorescence for PI inside the
Figure 5: Continued.
spheroids indicating dead cells in both cell types. In addition, the spheroid shape was changed from a compact circle in the control group to a less condensed one with an irregular surface. In a concentration-dependent manner, curcumin treatment reduced spheroid viability (Figure 2(b)), inhibited phosphorylation of MEK1/2 and ERK1/2, and downregulated the expression levels of HK-I, HK-II, PFKP, and PDH (Figure 2(c)) as well as complexes I NDUFB8, II succinate dehydrogenase complex iron sulfur subunit B (SDHB), III UQCRCC2, and IV COX II proteins in ETC (Figure 2(d)).

3.2. Effects of MEK/ERK Signaling Inhibition on the Antiglycolytic Activity of Curcumin. We investigated the relationship between the effect of curcumin on the MEK/ERK pathway and the glycolysis. Inhibition of the MEK1/2 activity by curcumin and/or PD98059 decreased cell viability (Figure 3(a)), along with decrease levels of p-MEK1/2 and p-ERK1/2 (Figure 3(b)). In addition, curcumin and/or PD98059 downregulated the levels of HK-I, HK-II, PFKP, and PDH (Figure 3(c)) as well as the activities of HK and PDH (Figure 3(d)). A decrease in the activity and concentration of these enzymes was accompanied by an increased glucose concentration in the culture medium compared to the vehicle-treated control, indicating a decrease in glucose utilization (Figure 3(e)).

3.3. Effects of MEK/ERK Signaling Inhibition on the Induction of Apoptosis and Necroptosis. To evaluate the type of cell death initiated by inhibition of the MEK/ERK pathway, cells treated with curcumin and/or PD98059 were analyzed by flow cytometric assay, Annexin V-PE binding assay, nuclear staining with DAPI, and Western blot. An increased percentage of the sub-G0/G1 fraction, indicative of cell death, in the cell cycle analysis was found compared to vehicle-treated controls (Figure 4(a)). In addition, an increase in Annexin V-PE(+) cells (Figure 4(b)) and cells with chromatin condensation and nuclear fragmentation (Figure 4(c)), indicative of apoptosis, was observed in the samples treated with curcumin and/or PD98059. Western blot analysis showed that the levels of proteins responsible for apoptosis, such as cleaved caspase-3 and cleaved PARP, and for necroptosis, such as p-MLKL and p-RIP3, were upregulated upon inhibition of MEK/ERK1/2 signaling (Figure 4(d)).

Next, we investigated whether inhibition of MEK/ERK pathway affects mitochondrial function. After 48 h of treatment with curcumin and/or PD98059, the loss of mitochondrial membrane potential, indicative of mitochondrial dysfunction, was significantly increased (Figure 5(a)), along with an increase in intracellular ROS levels (Figure 5(b)). Levels of mitochondrial ETC complexes I, III, and IV were downregulated in cells treated with curcumin but not changed in cells treated with PD98059 alone, suggesting that the MEK/ERK signaling pathway did not affect their expression (Figure 5(c)). Consistent with this, ATP content was significantly reduced in the samples treated with curcumin and/or PD98059 (Figure 5(d)).

3.4. Effects of MEK/ERK Signal Inhibition on the Antiglycolytic and Cytotoxic Role of Curcumin in 3D Spheroid Culture. We next validated the results of 2D monolayer cultures by studying the effect of ERK1/2 inhibition on the growth of spheroids and the expression of the glycolytic, apoptotic, and necroptotic protein in 3D spheroid cultures of PC-3AcT and Du145AcT cells. Figure 6(a) shows that treatment with curcumin and/or PD98059 reduced spheroid growth and increased red fluorescence of PI inside spheroids representing the necrotic core, whereas green fluorescence of FDA suggested living cells in the periphery. Consistent with this, the cell viability of 3D spheroids was higher than those of 2D cultured cells, indicating that 3D spheroids are more tolerant to curcumin and/or PD98059 (Figure 6(b)). Similar to the results of 2D culture mode, the levels of marker proteins for glucose metabolism, such as HK-I, HK-II, PFKP,
and PDH, for apoptosis, such as cleaved caspase-3 and cleaved PARP, and for necroptosis, such as p-MLKL and p-RIP3, were decreased in samples treated with curcumin and/or PD98059 (Figure 6(c)).

4. Discussion

In this experiment, curcumin was shown to induce simultaneously apoptosis and necroptosis by inhibiting both the
The glycolytic pathway and mitochondrial function in prostate carcinoma cells preadapted to lactic acid (Figure 7). We also demonstrated that ERK1/2 played an important role as an upstream regulator in this process. Since HK-II and PFKP act as important modulators of glycolytic flux, the decrease in their expression and activity along with increased glucose concentration in the culture medium in response to curcumin treatment accounts for the reduced glucose utilization. These changes in the glycolytic pathway impede cancer cell growth by lowering the provision of metabolic energy and intermediates for anabolic synthesis.

Upstream signaling pathways that regulate the antiglycolytic activity of curcumin have been reported for various cell types and in various cell contexts. In hepatic stellate cells, Lian et al. reported that curcumin inhibits aerobic glycolysis by downregulating HK, PFK-2, and glucose transporter (GLUT) 4 through the activation of AMPK [15]. Inhibition of glycolysis through the ROS/Yes-associated-protein (YAP)/c-Jun N-terminal kinase (JNK) pathway has been shown to be involved in antitumor activity of the curcumin analog WZ35 in gastric cancer cells [16]. In human colon cancer cells, it is known that curcumin inhibits glycolysis by inducing a decrease in the expression of HK-II. In this setting, Akt-induced phosphorylation of mitochondrial HK-II can play an important role in mitochondrial-mediated apoptosis by inducing the dissociation of HK-II from mitochondria [17]. Although the underlying mechanism(s) of the curcumin-induced deregulation of glycolytic enzymes have not yet been elucidated in prostate cancer cells, the results of this study, for the first time, demonstrate that the MEK/ERK signaling pathway can mediate the cross-talk between energy metabolism and cell death. MEK/ERK signaling plays an important role in tumorigenesis by promoting cell growth, survival, and tumor recurrence [18]. ERK1/2 signaling has been reported to promote induction of transcriptional regulators of glycolysis such as c-Myc and HIF-1α, downregulation of various glycolytic genes including GLUT1, GLUT3, and HK-II, or nuclear translocation of PKM2, which is the molecular basis linking ERK1/2 signaling to the Warburg effect in cancer cells [19]. Thus, blocking the active MEK/ERK pathway may provide mechanistic evidence for the antiglycolytic and cytotoxic roles of curcumin in prostate carcinoma cells. In the current study, the MEK inhibitor PD98059 was used to confirm the effect of curcumin. Except for the concentration and activity of HK-II, in which the combination treatment of curcumin and PD98059 showed a stronger effect than curcumin alone treatment in this study (Figures 3(c) and 3(d)), there was no significant difference between them in other experimental results. These results suggest that curcumin’s efficacy in inhibiting the glycolytic pathway in prostate carcinoma cells targets, at least in part, the MEK/ERK1/2 pathway.

Curcumin and/or PD98059 also inhibited cell growth and increased intracellular ROS levels with mitochondrial dysfunction, leading to upregulation of key molecules in apoptosis, such as cleaved caspase-3 and cleaved PARP, in necroptosis, such as p-MLKL and p-RIP3. These findings support the reports of other researchers that energy depletion by the inhibition of glycolysis resulted in apoptotic or nonapoptotic types of cancer cell death [20, 21] and
highlight the importance of targeting the glycolytic pathway in the treatment of prostate cancer. Interestingly, the combination of curcumin and PD98059 could not exert an additional effect compared with either curcumin or PD98059 alone, suggesting that a series of anticancer activities by curcumin may be mediated via inhibition of the MEK/ERK signaling pathway.

Inhibition of glycolysis in cancer cells usually induces an upregulation of mitochondrial function to compensate for the decrease in cellular energy production through glycolysis [22]. However, the decrease in the expression and activity of PDH following exposure to curcumin and/or PD98059, observed in the current study, reduce the formation of acetyl-CoA, the first reaction substrate of the TCA cycle, and moreover, concurrent downregulation of complexes I, III, and IV in the mitochondrial ETC may exacerbate ATP depletion, eventually leading to cell death. The coinhibitory effects on glycolysis and oxidative phosphorylation have also been observed in hepatocellular carcinoma cells with knocked down HK-II in combination with metformin [23].

Curcumin exerts chemotherapeutic effects on various types of cancers by disrupting mitochondrial homeostasis and enhancing cellular oxidative stress [24]. Glucose 6-phosphate, a product of the reaction catalyzed by HK, is the substrate for the initial reaction of the pentose phosphate pathway. Therefore, increased HK-II expression could reduce ROS by increasing flux through the pentose phosphate pathway which provides NADPH required for the production of reduced glutathione [25]. Conversely, inhibition of HK-II can augment the prooxidant state by decreasing the activity of the NADPH-generating pentose phosphate pathway. Although the specific mechanism by which curcumin acts as a prooxidant to induce ROS production in cancer cells remains to be elucidated, inhibition of HK-II may help increase ROS levels in curcumin-treated PC-3AcT cells.

5. Conclusion

Our results indicate that MEK/ERK signaling acts as a positive regulator of aerobic glycolysis in prostate cancer cells, suggesting a complex link between ERK1/2 and cellular energy metabolism. Therefore, inhibition of ERK1/2 activation seems to serve as an upstream event explaining the anti-glycolytic and cytotoxic roles of curcumin in prostate carcinoma cells preadapted to acidic conditions. It is important to note that curcumin promotes both apoptosis and necroptosis for prostate cancer cells exhibiting the Warburg phenotype by acting as a dual inhibitor of glycolysis and mitochondrial function.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Acknowledgments

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Education (Nos. NRF-2017R1D1A3B04031891 and NRF-2022R1F1A1069376).

References

[1] H. Pelicano, D. S. Martin, R. H. Xu, and P. Huang, “Glycolysis inhibition for anticancer treatment,” Oncogene, vol. 25, no. 34, pp. 4633–4646, 2006.
[2] O. Warburg, “Versuche an überlebendem carcinomgewebe,” Biochemische Zeitschrift, vol. 142, pp. 317–333, 1923.
[3] J. W. Locasale and L. C. Cantley, “Altered metabolism in cancer,” BMC Biology, vol. 8, no. 1, p. 8, 2010.
[4] S. Sutoo, T. Maeda, A. Suzuki, and Y. Kato, “Adaptation to chronic acidic extracellular pH elicits a sustained increase in lung cancer cell invasion and metastasis,” Clinical & Experimental Metastasis, vol. 37, no. 1, pp. 133–144, 2020.
[5] P. Vaupel and G. Multhoff, “The Warburg effect: historical dogma versus current rationale,” Advances in Experimental Medicine and Biology, vol. 1269, pp. 169–177, 2021.
[6] W. Yang, Y. Zheng, Y. Xia et al., “ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect,” Nature Cell Biology, vol. 14, no. 12, pp. 1295–1304, 2012.
[7] C. J. Caunt, M. J. Sale, P. D. Smith, and S. J. Cook, “MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road,” Nature Reviews. Cancer, vol. 15, no. 10, pp. 577–592, 2015.
[8] H. Ying, A. C. Kimmelman, C. A. Lyssiotis et al., “Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism,” Cell, vol. 149, no. 3, pp. 656–670, 2012.
[9] A. F. Abdel-Wahab, W. Mahmoud, and R. Al-Harizy, “Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy,” Pharmacological Research, vol. 150, article 104511, 2019.
[10] A. Mojzeš, M. Tomljanović, L. Milković, R. N. Kujundžić, A. Č. Gašparović, and K. G. Tröselj, “Cell-type specific metabolic response of cancer cells to curcumin,” International Journal of Molecular Sciences, vol. 21, no. 5, p. 1661, 2020.
[11] A. Shehzad and Y. S. Lee, “Molecular mechanisms of curcumin action: signal transduction,” BioFactors, vol. 39, no. 1, pp. 27–36, 2013.
[12] F. A. Siddiqui, G. Prakash, S. Chattopadhyay et al., “Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1α inhibition,” Scientific Reports, vol. 8, no. 1, p. 8323, 2018.
[13] Y. J. Lee, K. S. Park, and S. H. Lee, “Curcumin targets both apoptosis and necroptosis in acidity-tolerant prostate carcinoma cells,” BioMed Research International, vol. 2021, Article ID 8859181, 14 pages, 2021.
[14] Y. J. Lee and S. H. Lee, “Pro-oxidant activity of sulforaphane and cisplatin potentiates apoptosis and simultaneously promotes autophagy in malignant mesothelioma cells,” Molecular Medicine Reports, vol. 16, no. 2, pp. 2133–2141, 2017.
[15] N. Lian, H. Jin, F. Zhang et al., “Curcumin inhibits aerobic glycolysis in hepatic stellate cells associated with activation of
adenosine monophosphate-activated protein kinase,” *IUBMB Life*, vol. 68, no. 7, pp. 589–596, 2016.

[16] T. Chen, L. Zhao, S. Chen et al., “The curcumin analogue WZ35 affects glycolysis inhibition of gastric cancer cells through ROS-YAP-JNK pathway,” *Food and Chemical Toxicology*, vol. 137, article 111131, 2020.

[17] K. Wang, H. Fan, Q. Chen et al., “Curcumin inhibits aerobic glycolysis and induces mitochondrial-mediated apoptosis through hexokinase II in human colorectal cancer cells in vitro,” *Anti-Cancer Drugs*, vol. 26, no. 1, pp. 15–24, 2015.

[18] Y. Zhao and A. A. Adjei, “The clinical development of MEK inhibitors,” *Nature Reviews. Clinical Oncology*, vol. 11, no. 7, pp. 385–400, 2014.

[19] S. Papa, P. M. Choy, and C. Bubici, “The ERK and JNK pathways in the regulation of metabolic reprogramming,” *Oncogene*, vol. 38, no. 13, pp. 2223–2240, 2019.

[20] J. Cui, M. Yan, X. Liu et al., “Inorganic selenium induces non-apoptotic programmed cell death in PC-3 prostate cancer cells associated with inhibition of glycolysis,” *Journal of Agricultural and Food Chemistry*, vol. 67, no. 38, pp. 10637–10645, 2019.

[21] S. I. Ben, K. Laurent, and S. Giuliani, “Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells,” *Cancer Research*, vol. 70, no. 6, pp. 2465–2475, 2010.

[22] D. DeWaal, V. Nogueira, A. R. Terry et al., “Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin,” *Nature Communications*, vol. 9, no. 1, p. 446, 2018.

[23] N. Gupta, K. Verma, S. Nalla, A. Kulshreshtha, R. Lall, and S. Prasad, “Free radicals as a double-edged sword: the cancer preventive and therapeutic roles of curcumin,” *Molecules*, vol. 25, no. 22, p. 5390, 2020.

[24] D. Morin, S. Barthélémy, R. Zini, S. Labidalle, and J. P. Tillement, “Curcumin induces the mitochondrial permeability transition pore mediated by membrane protein thiol oxidation,” *FEBS Letters*, vol. 495, no. 1-2, pp. 131–136, 2001.

[25] R. B. Robey and N. Hay, “Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt,” *Oncogene*, vol. 25, no. 34, pp. 4683–4696, 2006.